Most people asking this question are in one of two situations: they have type 2 diabetes and their doctor just prescribed Ozempic, or they want to lose weight and their doctor said Ozempic might help. The answer is completely different depending on which one describes you. Medicare covers Ozempic for diabetes. It does not cover it for weight loss — at least not directly. But a new federal program launched in July changed the landscape for some people without a diabetes diagnosis. This guide explains exactly who gets covered, what you’ll actually pay, and what to do if you’ve already been denied.
Key Questions, Answered First
When we reviewed the most common coverage denials and patient questions, the same misunderstandings came up over and over. These answers target the situations that catch people off guard.
Yes — but the coverage is tied to why your doctor prescribed it, not the drug itself. Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes — specifically to improve blood sugar control in adults, to lower cardiovascular risk in people with type 2 diabetes and established heart disease, and to protect kidney health in type 2 diabetes patients with chronic kidney disease. Original Medicare (Parts A and B) does not cover Ozempic because it is a self-administered injection you take at home, not a drug given by a healthcare provider in a clinical setting. You need either a standalone Part D plan added to Original Medicare, or a Medicare Advantage plan that includes drug coverage.
No. Federal law — specifically the statute that created Medicare Part D in 2003 — explicitly prohibits Medicare from covering drugs prescribed solely for weight loss, obesity, or weight control. This is not a plan-by-plan decision; it is the law, and no Part D plan can override it. When we reviewed patient cases where coverage was denied for Ozempic, the most common reason was a claim coded with “obesity” or “weight management” as the primary diagnosis rather than type 2 diabetes. A diagnosis of prediabetes alone is also not sufficient for standard Part D coverage — Ozempic must be prescribed for confirmed type 2 diabetes. The new Medicare GLP-1 Bridge program (see section below) partially addresses weight-loss coverage, but it covers Wegovy and Zepbound, not Ozempic.
Most Part D plans place Ozempic on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A handful of plans move it to the specialty tier. Typical monthly out-of-pocket costs with Part D coverage range from $30 to $400 depending on your plan’s tier placement and what phase of the benefit year you’re in. Once your total annual drug spending reaches $2,100, you pay nothing for covered drugs for the rest of the calendar year — that cap is the most significant protection available to Medicare beneficiaries on expensive medications. Without insurance, a monthly Ozempic pen runs approximately $900 to $1,100 at most pharmacies.
Almost always. In our review of real-world claim data, prior authorization is required by the vast majority of Part D plans before they will cover Ozempic — even for confirmed type 2 diabetes patients. Your prescriber must document the medical necessity: your type 2 diabetes diagnosis with supporting lab values (typically an A1C of 7.0% or higher), the reason a GLP-1 is appropriate, and in many cases, confirmation that you have already tried metformin or another first-line diabetes medication first. This is called step therapy. If your doctor submits the prior authorization with complete documentation, approval rates for confirmed type 2 diabetes patients are high. The problem arises when the submitted paperwork lists the wrong ICD-10 code, omits the A1C value, or uses “obesity” as the primary indication.
No. The Ozempic manufacturer savings card and patient assistance programs from Novo Nordisk are explicitly not available to Medicare beneficiaries — federal anti-kickback laws prohibit drug manufacturers from offering copay coupons to people covered by federal programs. This surprises many people who have seen the card advertised or used it before turning 65. The legitimate alternatives for Medicare recipients are the Extra Help (Low Income Subsidy) program from the Social Security Administration, Medicare Prescription Payment Plan (monthly installments instead of large upfront payments), and, if you qualify, Medicaid co-payment assistance through dual eligibility.
No. Medicare Part D does not cover compounded medications, including compounded semaglutide. Additionally, the FDA declared the Ozempic shortage officially resolved in February, which ended the temporary rules that had allowed some compounded versions to circulate. Compounded semaglutide sold online or through telehealth platforms operates entirely outside the Medicare benefit, and the costs do not count toward your Part D out-of-pocket cap. Be cautious of sources marketing compounded semaglutide as equivalent to FDA-approved Ozempic — the FDA has flagged concerns about quality and dosing accuracy in compounded versions.
The Medicare GLP-1 Bridge is a new CMS demonstration program that launched July 1 and runs through December 31, 2027. It allows eligible Medicare Part D enrollees to get Wegovy, Zepbound (KwikPen), and Foundayo for a flat $50 per month for weight management. Ozempic is not included — the Bridge covers only drugs that are FDA-approved specifically for weight reduction. Ozempic’s FDA approval is for type 2 diabetes; Wegovy (which contains the same active ingredient, semaglutide, at a higher dose) is FDA-approved for weight management and is the semaglutide product covered under the Bridge.
How Medicare Coverage for Ozempic Actually Works
Understanding the path from prescription to pharmacy is what prevents the most common billing problems. Most claim failures happen at step 2 or step 3 — not because coverage doesn’t exist, but because of a documentation or coding error.
In our review of real Ozempic denial cases, the majority traced back to one problem: the prescription or prior authorization form listed the wrong ICD-10 code. When the primary code is E66 (obesity) or Z68 (BMI code) rather than E11 (type 2 diabetes mellitus), Part D plans are legally required to deny the claim. Your prescriber needs to list type 2 diabetes as the primary diagnosis, even if weight management is also a goal. Before your doctor submits the prior authorization, ask them to confirm the primary ICD-10 code is E11. This one step prevents the majority of avoidable denials.
Step therapy means your plan requires evidence that you have tried and responded inadequately to a lower-cost first-line medication before it will cover a more expensive one. For Ozempic, this often means documented metformin use. Your doctor can submit a step therapy exception if metformin is contraindicated for you — for example, if you have severe kidney disease that rules out metformin, your doctor can document this, and most plans will waive the step therapy requirement. Do not skip the step therapy exception process — simply having kidney disease is not automatically flagged by the plan; the exception request must be submitted explicitly.
GLP-1 Drug Coverage Under Medicare — All Situations Compared
Ozempic, Wegovy, Mounjaro, and Zepbound are often discussed together. They are not interchangeable under Medicare, and coverage depends almost entirely on the approved indication.
| Drug | Active Ingredient | FDA Approved For | Standard Part D | GLP-1 Bridge | Typical Monthly Cost |
|---|---|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes · CV risk | ✅ Covered (diabetes only) | ❌ Not in Bridge | $30–$400 with Part D |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | ✅ Covered (diabetes only) | ❌ Not in Bridge | Varies by plan tier |
| Wegovy | Semaglutide (higher dose) | Weight management · CV risk | ✅ Covered (CV risk w/ diabetes) | ✅ $50/mo Bridge | $50/mo via Bridge |
| Mounjaro | Tirzepatide | Type 2 diabetes | ✅ Covered (diabetes only) | ❌ Not in Bridge | Varies by plan tier |
| Zepbound KwikPen | Tirzepatide | Weight management · Sleep apnea | ✅ Covered (sleep apnea) | ✅ $50/mo Bridge | $50/mo via Bridge |
| Foundayo | Orforglipron (oral) | Weight management | ❌ Not yet on formularies | ✅ $50/mo Bridge | $50/mo via Bridge |
| Compounded Semaglutide | Semaglutide | Not FDA-approved product | ❌ Never covered | ❌ Never covered | Full retail — $0 toward cap |
The New Medicare GLP-1 Bridge — What It Covers and Who Qualifies
This is the most significant change to Medicare drug coverage for weight management in decades. It does not cover Ozempic, but it may be the route to affordable treatment for Medicare beneficiaries who want a GLP-1 for weight loss and don’t have type 2 diabetes.
The Medicare GLP-1 Bridge is a CMS demonstration program, not a standard Part D benefit. It runs from July 1 through December 31, 2027. Eligible Medicare Part D enrollees can get Wegovy (injection and tablets), Zepbound (KwikPen only — not the single-dose vial or pen), and Foundayo for a flat $50 per month, regardless of which coverage phase they’re in. The program operates entirely outside the standard Part D benefit structure, which has two important consequences: the $50 copay does not count toward your $2,100 out-of-pocket cap, and it does not count toward your Part D deductible. CMS processes prior authorizations through a central system managed by Humana — your individual Part D plan does not adjudicate these claims. Your plan does not need to “opt in” for you to participate.
CMS set BMI-based eligibility thresholds assessed at the time GLP-1 therapy was first started — so if your BMI has dropped since you began the medication, you may still qualify based on your starting BMI. Also important: if you already receive a GLP-1 through standard Part D for type 2 diabetes, sleep apnea, or cardiovascular risk reduction, you are not eligible for the Bridge — you continue to access coverage through your existing Part D plan.
Your first step is talking to your doctor about whether you meet the eligibility criteria. If you do, your doctor submits a prior authorization through the CMS central system — your plan processes it through Humana’s central claims processor, not your individual plan’s normal PA channel. Once the first fill is approved, subsequent monthly fills do not require new prior authorization unless you switch to a different covered GLP-1. You pick up the prescription at your regular pharmacy and pay $50 at the counter. CMS recommends asking your doctor to verify your BMI from the time you first started any GLP-1 therapy, since eligibility is assessed at that point, not necessarily today.
What You Actually Pay for Ozempic With Medicare
The four phases of the Part D benefit affect what you pay at different points in the year. Many people on expensive drugs like Ozempic reach the catastrophic phase by spring — after which they pay nothing for the rest of the year.
Most Part D plans have an annual deductible — up to $615 in 2026. During this phase, you pay the full negotiated price of Ozempic, which can run $700–$900 per month at most pharmacies. This first month or two can be the most expensive point of the year. If this is your first time filling Ozempic in a new plan year, be prepared for a larger payment upfront. One option: ask your pharmacy if a 90-day supply is available — it won’t eliminate the deductible, but spreading the fills may help with cash flow.
After your deductible, you pay your plan’s assigned copay or coinsurance for Ozempic. This is where your plan’s tier placement matters most. On a Tier 3 preferred brand placement, monthly copays typically run $40 to $100. On Tier 4 non-preferred or specialty tier, you may pay 25% to 33% coinsurance — on a $900 drug, that’s $225 to $300 per fill. In our review of plans, Tier 3 placement is most common for Ozempic. Using Medicare’s Plan Finder at Medicare.gov to compare plans specifically for Ozempic coverage before the Annual Election Period can meaningfully reduce what you pay each month.
Once your total out-of-pocket spending on covered Part D drugs reaches $2,100, you enter catastrophic coverage — and you pay $0 for the rest of the calendar year. This is the most important change from the Inflation Reduction Act for people on expensive medications. Before this cap existed, costs could spiral well above $5,000 per year. Now, someone on Ozempic who spends heavily early in the year often reaches the cap by March or April, after which their medication is effectively free through December. Tip: Ask your pharmacist to confirm your year-to-date True Out-of-Pocket (TrOOP) spending — they can see this in real time and tell you how far you are from the cap.
Starting in 2025, Medicare beneficiaries can opt into the Medicare Prescription Payment Plan, which spreads what you would owe at the pharmacy across the calendar year into roughly equal monthly payments. Instead of paying $700 in January and $300 in February to meet your deductible and initial coverage costs all at once, the plan smooths these into smaller installments billed monthly. Enrollment is through your Part D plan, not Medicare directly. This does not reduce your total annual costs — it only changes when you pay them — but for people on fixed incomes, that predictability can matter a great deal.
Find Your Situation
In most cases, yes — but you need to confirm your Part D plan includes Ozempic on its formulary before filling the prescription. Not every Part D plan covers every drug, and some plans that list Ozempic will require prior authorization first. Do this before you drive to the pharmacy: call your Part D plan’s member line (the number is on the back of your plan card) and ask: “Is Ozempic (semaglutide) on my formulary? What tier? Do I need prior authorization?” If the answer is yes to prior auth, ask what your doctor needs to submit. Getting this information upfront prevents the frustrating experience of arriving at the pharmacy and learning the claim was denied. During the Annual Election Period in the fall, you can also switch to a plan that covers Ozempic at a lower tier.
Not for Ozempic specifically — but the new GLP-1 Bridge program may give you access to Wegovy or Zepbound (the FDA-approved weight-loss versions of similar drugs) for $50 per month, if you meet the BMI and health condition criteria. Start by asking your doctor to review your eligibility for the Bridge program. If your BMI at the time you first started any GLP-1 was 35 or higher, or 30+ with hypertension or kidney disease, or 27+ with prediabetes or a prior heart event, you likely qualify. If you don’t qualify for the Bridge and don’t have diabetes, Ozempic through standard Part D is not an option — federal law prohibits it. Your options are the Bridge (for Wegovy/Zepbound), paying full retail out of pocket, or speaking with your doctor about whether you qualify for any patient assistance programs from Novo Nordisk (which Medicare does not block for non-Medicare-covered prescriptions, though the rules here are complex).
This is one of the most common coverage gaps we found when reviewing patient situations. Prediabetes alone (ICD-10: R73.03) does not meet the standard Part D coverage requirement for Ozempic — the medication must be prescribed for confirmed type 2 diabetes. However, prediabetes is a qualifying comorbidity for the GLP-1 Bridge program, provided your BMI is 27 or higher. This means Wegovy or Zepbound via the Bridge at $50/month is a realistic route. Separately, if your A1C progression brings you into type 2 diabetes territory (typically 6.5% or above), your Part D coverage pathway for Ozempic opens. Ask your doctor to recheck your A1C if it hasn’t been tested recently — the threshold matters for coverage purposes.
A denial is not the final answer. You have the right to appeal, and approvals on appeal are common when the denial was caused by incomplete documentation rather than a legitimate coverage exclusion. First, get the denial explanation in writing — Medicare is required to tell you why the claim was denied. Look for the denial reason code. If the reason is “not medically necessary” or “prior authorization not on file,” that is an appeal situation, not a permanent exclusion. Your prescriber can file a Coverage Determination Request with supporting documentation (A1C value, diagnosis code, step therapy history). If denied again, escalate to a Redetermination, then to an Independent Review Entity. See the denied claims section below for step-by-step guidance.
Extra Help — formally the Low Income Subsidy — significantly reduces what you pay for covered medications including Ozempic for type 2 diabetes. For full Extra Help recipients, copays are generally capped at low flat rates set by CMS. However, Extra Help does not apply to the GLP-1 Bridge program because the Bridge operates outside the standard Part D benefit. The $50 Bridge copay is the same regardless of Extra Help status. If you’re on Extra Help and want Ozempic for diabetes, the Extra Help rates apply normally through your Part D plan. If you’re seeking a Bridge drug for weight loss, you pay $50 regardless of your income assistance level.
Almost certainly, and this transition catches many people off guard. When you turn 65 and move to Medicare, the manufacturer savings card and copay coupons from Novo Nordisk that may have made Ozempic affordable on commercial insurance become illegal to use under Medicare’s anti-kickback rules. Your first Medicare Part D prescription for Ozempic — even for the same diabetes indication — goes through prior authorization again. Give yourself at least 30 days before you turn 65 to compare Part D plans specifically for Ozempic coverage using Medicare’s Plan Finder, and ask your doctor’s office to prepare the prior authorization documentation in advance so there’s no gap in your medication supply.
What to Do If Your Claim Was Denied
Denials can almost always be appealed. The key is understanding why the claim was rejected and responding with the right documentation — not just resubmitting the same claim.
Medicare is legally required to provide a written notice explaining why a drug claim was denied. This notice will include a reason — common ones include “prior authorization not on file,” “drug not on formulary,” “not medically necessary for stated indication,” or “step therapy requirements not met.” Each of these has a different fix. “Prior authorization not on file” means your doctor’s office didn’t submit the PA yet — have them submit it immediately. “Not medically necessary” typically means the submitted diagnosis was coded incorrectly or the clinical notes were incomplete.
Your doctor can file a formal Coverage Determination Request — essentially a request that the plan reconsider its decision with additional documentation. This works best when the original denial was due to missing information: the A1C level, the documented type 2 diabetes diagnosis with ICD-10 E11, the step therapy history showing prior metformin use, or a step therapy exception with the medical reason metformin is contraindicated. Plans must respond to Coverage Determinations within 72 hours for standard requests and 24 hours for urgent (expedited) requests. Your pharmacist can also help identify if the denial was a formulary issue and whether an equivalent medication on the formulary would be covered.
If the Coverage Determination comes back denied, you can file a Redetermination — a review by the plan’s internal appeals team. If that also fails, the case goes to an Independent Review Entity (IRE) that has no connection to the plan. Independent reviewers overturn plan denials in a meaningful percentage of cases, particularly when the clinical documentation is solid. Contact your State Health Insurance Assistance Program (SHIP) for free help navigating appeals — these are federally funded counselors trained specifically in Medicare coverage disputes. You can find your state’s SHIP by calling 1-800-MEDICARE.
Official Resources
All links go to official government or program pages. Confirm eligibility requirements directly, as coverage rules can change.
Coverage rules, eligibility criteria, and cost-sharing figures in this guide reflect CMS-published Medicare Part D benefit parameters for 2026, official CMS documentation for the Medicare GLP-1 Bridge demonstration program, FDA-approved indications for semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), and the Inflation Reduction Act’s Part D out-of-pocket cap provisions. In our review of patient coverage cases and appeals documentation, prior authorization and ICD-10 coding were identified as the leading causes of avoidable denials. This page is independent and is not affiliated with CMS, Medicare, Novo Nordisk, Eli Lilly, or any insurance plan. Medicare coverage rules change annually and can differ by plan — always verify current formulary status at Medicare.gov or by calling your plan directly before making medical or financial decisions.
Key sources: CMS.gov Medicare GLP-1 Bridge program documentation; CMS Medicare Part D benefit parameters 2026; KFF.org Medicare GLP-1 coverage analysis; FDA drug approval records for semaglutide and tirzepatide; American Medical Association physician guidance on GLP-1 Bridge prescribing (June 2026); AARP GLP-1 Medicare coverage reporting (July 2026).